Background: Accurate prognostic stratification of human papillomavirus-associated oropharyngeal cancers (HPV+OPSCC) is required to identify patients potentially suitable for treatment deintensification. We evaluated the prognostic significance of CD103, a surface marker associated with tissue-resident memory T cells (TRMs), in two independent cohorts of patients with HPV+OPSCC.
Patients And Methods: The abundance and distribution of CD103+ immune cells were quantified using immunohistochemistry in a cohort of 189 HPV+OPSCC patients treated with curative intent and correlated with outcome. Findings were then validated in an independent cohort comprising 177 HPV+OPSCCs using univariable and multivariable analysis. Intratumoral CD103+ immune cells were characterized by multispectral fluorescence immunohistochemistry and gene expression analysis.
Results: High intratumoral abundance of CD103+ immune cells using a ≥30% cut-off was found in 19.8% of tumors in the training cohort of HPV+OPSCC patients and associated with excellent prognosis for overall survival (OS) with adjusted hazard ratio (HR) of 0.13 [95% confidence interval (CI) 0.02-0.94, P = 0.004]. In the independent cohort of HPV+OPSCCs, 20.4% had high intratumoral CD103+ abundance and an adjusted HR for OS of 0.16 (95% CI 0.02-1.22, P = 0.02). Five year OS of patients with high intratumoral CD103 was 100% across both cohorts. The C-statistic for the multivariate prognostic model with stage and age was significantly improved in both cohorts with the addition of intratumoral CD103+ cell abundance. On the basis of spatial location, co-expression of CD8 and CD69, and gene expression profiles, intratumoral CD103+ cells were consistent with TRMs.
Conclusion: Quantification of intratumoral CD103+ immune cell abundance provides prognostic information beyond that provided by clinical parameters such as TNM-staging, identifying a population of low risk HPV+OPSCC patients who are good candidates for trials of deintensification strategies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/annonc/mdz271 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intratumoral Injection of Engineered Induces Antitumor Immunity and Inhibits Tumor Growth.
Biomater Res
January 2024
The Comprehensive Cancer Centre, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China.
Conventional type 1 dendritic cells are essential for antigen presentation and successful initiation of antitumor CD8 T cells. However, their abundance and function within tumors tend to be limited. , a fast-growing, nonpathogenic mycobacterium, proves to be easily modified with synthetic biology.
View Article and Find Full Text PDFDifferential predictive value of resident memory CD8T cell subpopulations in patients with non-small-cell lung cancer treated by immunotherapy.
J Immunother Cancer
December 2024
Université Paris Cité, INSERM, PARCC, Paris, France, Paris, France
Article Synopsis
- Tumor-infiltrating memory T cell subpopulations in non-small cell lung cancer (NSCLC) can be categorized based on various surface markers, with CD103 often used but not universally expressed.
- In studies, multiparametric cytometry and multiplex immunofluorescence techniques were applied to analyze T-cell behavior in vaccinated mice and human NSCLC patients, revealing distinct subpopulations and their impact on clinical outcomes.
- Results showed that a specific double-positive T cell subset (CD103+CD49a+) was more functional than a single-positive subset (CD49a+), with implications for predicting responses to immunotherapy, particularly relating to PD-1 treatment.
Low-Dose Eribulin Promotes NK Cell-Mediated Therapeutic Efficacy in Bladder Cancer.
Cancers (Basel)
November 2024
Department of Urology, University of Texas Health San Antonio (UTHSA), San Antonio, TX 78229, USA.
Unlabelled: Despite its immunogenic nature, bladder cancer (BCa) responds sub-optimally to FDA-approved immunotherapy.
Background/objectives: We have previously shown that natural killer (NK) cells are major contributors to overall patient survival in BCa. In our efforts to identify clinically approved agents that enhance NK cell activation, we identified eribulin, a microtubule destabilizer primarily used in breast cancer.
CD103 cDC1 Dendritic Cell Vaccine Therapy for Osteosarcoma Lung Metastases.
Cancers (Basel)
September 2024
Department of Pediatrics Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Background: We generated a CD103DC vaccine using K7M3 OS cell lysates (cDCV) and investigated its ability to induce regression of primary tumors, established lung metastases, and a systemic immune response.
Methods: A bilateral tumor model was used to assess cDCV therapy efficacy and systemic immunity induction. K7M3 cells were injected into mice bilaterally.
Spatial proteomic landscape of primary and relapsed hepatocellular carcinoma reveals immune escape characteristics in early relapse.
Hepatology
June 2024
Department of Nuclear Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong, China.
Article Synopsis
- Surgical resection is the main treatment for hepatocellular carcinoma (HCC), but recurrence after surgery is frequent, and the reasons for this are not fully understood.
- Researchers used advanced imaging techniques to analyze 358,729 cells from surgical specimens of 46 HCC patients, revealing that the distribution and interaction of various cell types within different tumor regions influence the likelihood of recurrence.
- They discovered a specific type of dendritic cell associated with early postoperative recurrence and highlighted the role of the tumor microenvironment in promoting immune suppression, which contributes to HCC relapse.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!